Identification of ATIC as a Novel Target for Chemoradiosensitization.

Abstract

PURPOSE:

Mutations in the gene encoding 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase (ATIC), a bifunctional enzyme that catalyzes the final 2 steps of the purine de novo biosynthetic pathway, were identified in a subject referred for radiation sensitivity testing. Functional studies were performed to determine whether ATIC inhibition was radiosensitizing and, if so, to elucidate the mechanism of this effect and determine whether small molecule inhibitors of ATIC could act as effective radiosensitizing agents.

METHODS AND MATERIALS:

Both small interfering RNA knockdown and small molecule inhibitors were used to inactivate ATIC in cell culture. Clonogenic survival assays, the neutral comet assay, and γH2AX staining were used to assess the effects of ATIC inhibition or depletion on cellular DNA damage responses.

RESULTS:

Depletion of ATIC or inhibition of its transformylase activity significantly reduced the surviving fraction of cells in clonogenic survival assays in multiple cancer cell lines. In the absence of ionizing radiation exposure, ATIC knockdown or chemical inhibition activated cell cycle checkpoints, shifting cells to the more radiosensitive G2/M phase of the cell cycle, and depleted cellular adenosine triphosphate but did not result in detectable DNA damage. Cells in which ATIC was knocked down or inhibited and then treated with ionizing radiation displayed increased numbers of DNA double-strand breaks and a delay in the repair of those breaks relative to irradiated, but otherwise untreated, controls. Supplementation of culture media with exogenous adenosine triphosphate ameliorated the DNA repair phenotypes.

CONCLUSIONS:

These findings implicate ATIC as an effective, and previously unrecognized, target for chemoradiosensitization and, more broadly, suggest that purine levels in cells might have an underappreciated role in modulating the efficiency of DNA damage responses that could be exploited in radiosensitizing strategies.

• Authors: Xiangfei Liu, Uma Devi Paila, Sharon N Teraoka, Jocyndra A Wright, Xin Huang, Aaron R Quinlan, Richard A Gatti, Patrick Concannon
• Journal: International journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) Vol. 100 Issue 1 Pg. 162-173 (01 01 2018) ISSN: 1879-355X [Electronic] United States
• PMID: 29029884 (Publication Type: Journal Article)
• Copyright: Copyright © 2017 Elsevier Inc. All rights reserved.

Chemical References

• Enzyme Inhibitors
• H2AX protein, human
• Histones
• Multienzyme Complexes
• Neoplasm Proteins
• Radiation-Sensitizing Agents
• inosine monophosphate synthase
• Adenosine Triphosphate
• Hydroxymethyl and Formyl Transferases
• Nucleotide Deaminases

Topics

• Adenosine Triphosphate (administration & dosage)
• Cell Cycle Checkpoints (physiology)
• Cell Line, Tumor
• Cell Survival (genetics)
• Chemoradiotherapy
• Comet Assay
• DNA Breaks, Double-Stranded
• DNA Damage
• DNA Repair
• Enzyme Inhibitors (therapeutic use)
• Frameshift Mutation
• Gene Knockdown Techniques
• Histones (analysis)
• Humans
• Hydroxymethyl and Formyl Transferases (antagonists & inhibitors, deficiency, genetics)
• Molecular Targeted Therapy (methods)
• Multienzyme Complexes (antagonists & inhibitors, deficiency, genetics)
• Neoplasm Proteins (antagonists & inhibitors, deficiency, genetics)
• Nucleotide Deaminases (antagonists & inhibitors, deficiency, genetics)
• Radiation-Sensitizing Agents (therapeutic use)
• Tumor Stem Cell Assay